Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres

Area of Science:

• Interventional Radiology
• Hepatobiliary Oncology
• Medical Device Research

Background:

• Transarterial chemoembolization (TACE) and transarterial embolization (TAE) are standard treatments for unresectable hepatocellular carcinoma (HCC).
• The selection of an optimal embolic agent for TAE remains an area of active investigation.
• Microspheres (ME) and polyvinyl alcohol (PVA) are commonly used embolic agents in TAE procedures.

Purpose of the Study:

• To compare the efficacy and safety of microspheres (ME) versus polyvinyl alcohol (PVA) as embolic agents in transarterial embolization (TAE) for hepatocellular carcinoma (HCC).
• To evaluate the impact of ME-TAE and PVA-TAE on patient survival, tumor response, and complication rates.

Main Methods:

• Retrospective study of 80 patients with unresectable HCC who underwent TAE between June 2008 and December 2012.
• Patients were divided into two groups: 48 treated with PVA and 32 treated with ME.
• Outcomes assessed included overall survival, tumor response, and incidence of postembolization syndrome.

Main Results:

• No statistically significant differences were observed in overall survival (P = 0.679) or tumor response (P = 0.369) between the PVA and ME groups.
• Five-year survival rates were comparable, with 21.4% in the PVA group and 58% in the ME group (P = 0.734).
• Patients treated with ME experienced a higher incidence of postembolization syndrome compared to those treated with PVA (P = 0.02).

Conclusions:

• The choice between ME and PVA as an embolic agent for TAE in HCC does not significantly affect overall survival.
• While both agents demonstrate comparable survival outcomes, ME use is associated with a higher risk of postembolization syndrome.
• Further research may explore patient selection criteria to optimize embolic agent choice in HCC treatment.